- Trials with a EudraCT protocol (235)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
235 result(s) found for: glioblastoma.
Displaying page 10 of 12.
| EudraCT Number: 2011-004974-27 | Sponsor Protocol Number: BP28015 | Start Date*: 2012-03-26 | |||||||||||
| Sponsor Name:University Medical Center Groningen | |||||||||||||
| Full Title: 89Zr-RO5323441 PET imaging in patients with recurrent glioblastoma treated with bevacizumab | |||||||||||||
| Medical condition: Recurrent malignant glioma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-005077-21 | Sponsor Protocol Number: DCOG 0423 | Start Date*: 2007-02-12 |
| Sponsor Name:Dutch Childhood Oncology Group (DCOG) | ||
| Full Title: A Phase II study of concurrent radiation and Temozolomide followed by Temozolomide and Lomustine (CCNU) in the treatment of Children with High Grade Glioma | ||
| Medical condition: High grade glioma: anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-000365-37 | Sponsor Protocol Number: MIN-003-1806 | Start Date*: 2019-06-04 | |||||||||||
| Sponsor Name:Lipopharma Therapeutics | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with ... | |||||||||||||
| Medical condition: Newly diagnosed primary glioblastoma multiforme (ndGBM) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-000814-23 | Sponsor Protocol Number: CLDK378A2407 | Start Date*: 2015-10-26 |
| Sponsor Name:Novartis Farmacéutica, S.A. | ||
| Full Title: A Phase II, open label, multi-center, multi-arm study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of anaplastic lymphom... | ||
| Medical condition: Advanced solid tumors and hematological malignancies with ALK genetic alteration and/or overexpression | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Prematurely Ended) DE (Temporarily Halted) CZ (Completed) FR (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-002931-27 | Sponsor Protocol Number: I3Y-MC-JPCS | Start Date*: 2020-10-03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Rela... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Pediatric and Young Adult Patients Relapsed/Refractory Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) DE (Trial now transitioned) IT (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-005387-25 | Sponsor Protocol Number: noprofit1616 | Start Date*: 2016-05-05 | |||||||||||
| Sponsor Name:Sapienza, University of Rome | |||||||||||||
| Full Title: Phase 2a Study of an Immunotherapeutic Vaccine, DPX-Survivac, Alone or with Low dose Cyclophosphamide in Primary Glioblastoma Patients Receiving Standard of Care Therapy | |||||||||||||
| Medical condition: Glioblastoma is the most common primary brain tumour in humans with the most severe prognosis. Standard treatments consist primarily of surgery in order to debulk thetumoral mass, as well as radioc... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-003602-16 | Sponsor Protocol Number: PM1183-A-014-15 | Start Date*: 2022-02-24 | |||||||||||
| Sponsor Name:Pharma Mar S.A. | |||||||||||||
| Full Title: Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors. | |||||||||||||
| Medical condition: Selected Advanced Solid Tumors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) DE (Completed) AT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-010337-45 | Sponsor Protocol Number: GENOM-009 | Start Date*: 2009-06-26 |
| Sponsor Name:GRUPO ESPAÑOL DE NEUROONCOLOGIA MEDICA | ||
| Full Title: Ensayo Clínico, fase II aleatorizado de tratamiento neo-adyuvante con 2 ciclos de temozolomida a dosis extendidas, previos al tratamiento con temozolomida más irradiación y posterior adyuvancia con... | ||
| Medical condition: Glioblastoma no resecable | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-003925-13 | Sponsor Protocol Number: CA209-9UP | Start Date*: 2018-02-19 |
| Sponsor Name:Rigshospitalet | ||
| Full Title: A phase II Open Label, two-armed Translational Study of Nivolumab in Combination with Bevacizumab for Recurrent Glioblastoma | ||
| Medical condition: Glioblastoma, recurrent/progressive | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-000739-97 | Sponsor Protocol Number: HIC | Start Date*: 2011-05-05 |
| Sponsor Name:Med. Univ. Wien | ||
| Full Title: Prospective, randomized, controlled, open-label study evaluating quality of life in patients with advanced malignant tumors with and without “add-on” homeopathy | ||
| Medical condition: Homeopathic remedies as add on therapie in cancer | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-004392-11 | Sponsor Protocol Number: ULg_GBM_04/1 | Start Date*: 2005-03-03 |
| Sponsor Name:Centre Hospitalier Universitaire de Liege | ||
| Full Title: Human phase 1/2 clinical study of the safety and efficacy of sulfasalazine as a therapy for recurrent or progressing high grade gliomas. | ||
| Medical condition: Recurrent or progressive high grade glioma, including gliobastoma, anaplastic astrocytoma and oligo-astrocytoma. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-019051-21 | Sponsor Protocol Number: ML25152 | Start Date*: 2010-05-18 |
| Sponsor Name:Roche Farma, S.A. | ||
| Full Title: Estudio de un único brazo, fase II de bevacizumab en combinación con temozolomida en pacientes con glioblastoma multiforme recurrente | ||
| Medical condition: Pacientes con glioblastoma multiforme recurrente. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-016813-11 | Sponsor Protocol Number: AOBS-RT-TMZ | Start Date*: 2010-01-22 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | |||||||||||||
| Full Title: Randomized prospectic clinical trial Phase II in patients affected by prognostic class RPA V and VI glioblastoma: comparison between hypofractionated radiotherapy (RT) 30 Gy (6 fractions in two wee... | |||||||||||||
| Medical condition: Patients with histological diagnosis od glioblastoma in RPA class V and VI and age =>65 yrs. | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-001278-26 | Sponsor Protocol Number: VEG102857 | Start Date*: 2006-10-31 |
| Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
| Full Title: Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma | ||
| Medical condition: Relaped Malignant Glioma = patients with anaplastic astrocytoma, anaplastic oligodendroglioma, mixed anaplastic oligoastrocytoma, glioblastoma multiforme or gliosarcoma at recurrence | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-000547-24 | Sponsor Protocol Number: CCRG11-001 | Start Date*: 2012-02-27 | ||||||||||||||||
| Sponsor Name:Antwerp University Hospital | ||||||||||||||||||
| Full Title: Therapeutic efficacy of Wilms' tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with solid tumors: a phase I/feasibility study | ||||||||||||||||||
| Medical condition: Therapeutic vaccination with dendritic cells loaded with Wilms' tumor 1 protein in patients with solid tumors | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2018-003747-37 | Sponsor Protocol Number: MK-7902-005 | Start Date*: 2019-03-07 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005) | |||||||||||||
| Medical condition: Triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), or biliary tract cancers (BTC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-000390-67 | Sponsor Protocol Number: ACT15377 | Start Date*: 2020-01-13 | |||||||||||
| Sponsor Name:Sanofi-aventis recherche & développement | |||||||||||||
| Full Title: A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with adv... | |||||||||||||
| Medical condition: Neoplasm | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) BE (Completed) NL (Completed) ES (Ongoing) GR (Prematurely Ended) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-002600-41 | Sponsor Protocol Number: CSTI571H2201 | Start Date*: 2006-01-17 |
| Sponsor Name:Novartis Farmacéutica, S.A. | ||
| Full Title: Estudio fase II, abierto, multicéntrico, no comparativo, que evalúa la eficacia de Glivec® con Hidroxiurea en pacientes con Glioblastoma Multiforme (GBM) en progresión, que no reciben fármacos anti... | ||
| Medical condition: Glioblastoma multiforme progresivo (GBM) tras fallo a terapia de primera línea definida por cirugía, radioterapia y exposición a un régimen de quimioterapia de Temozolamida (TMZ). | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) BE (Completed) SE (Completed) DE (Completed) DK (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-002603-16 | Sponsor Protocol Number: CSTI571H2202 | Start Date*: 2006-01-17 |
| Sponsor Name:Novartis Farmacéutica, S.A. | ||
| Full Title: Estudio fase II, abierto, multicéntrico, no comparativo, que evalúa la eficacia de Glivec® con Hidroxiurea en pacientes con Glioblastoma Multiforme (GBM) en progresión, que reciben fármacos anticon... | ||
| Medical condition: Glioblastoma multiforme progresivo (GBM) tras fallo a terapia de primera línea definida por cirugía, radioterapia y exposición a un régimen de quimioterapia de Temozolamida (TMZ). | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) BE (Completed) SE (Completed) DE (Completed) DK (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-002262-39 | Sponsor Protocol Number: 131I-IPA-TLX-101-001 | Start Date*: 2018-10-24 |
| Sponsor Name:TELIX International Pty Ltd | ||
| Full Title: A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I... | ||
| Medical condition: 2nd line therapy of recurrent GBM (Glioblastoma multiforme), scheduled for repeat XRT. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) NL (Completed) BE (Completed) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
